History

Vectura acquired Co-ordinated Drug Development Limited, owned by a group of academic pharmaceutical scientists, and the Centre for Drug Formulation Studies, established at the University of Bath. These two acquisitions provided a broad base of formulation expertise focused primarily on drugs for inhalation, an extensive intellectual property estate including a number of novel delivery technologies, an established development services business, and a team of research scientists.

Vectura collaborated with Arakis Ltd (now part of Sosei Group Corporation) in the development of AD237 (later NVA237) for the treatment of COPD.

Vectura acquired the Aspirair® inhaler technology and the associated device engineering team from Cambridge Consultants Ltd. Later that year Vectura moved to purpose-built premises in Chippenham.

Vectura listed on the London Stock Exchange on AiM.

Vectura entered into its first global commercialisation and development agreement with Novartis for NVA237.

Vectura entered significant licence and product development agreements with Boehringer Ingelheim and other major international pharmaceutical company partners based on Vectura’s proprietary device technologies and formulation development expertise.

Vectura acquired Innovata plc, a UK listed company that was developing pulmonary products using specialised device and formulation technologies and with a portfolio of marketed, revenue-generating products.  In July 2007 Vectura moved from AIM to the Official List on the London Stock Exchange.

Vectura and its partners continued to make good clinical progress announcing positive Phase II data for NVA237.  In addition, Sandoz was confirmed as partner for the generic asthma/COPD product, VR315.

Vectura and its partners continue to make good clinical progress announcing positive Phase II date with QVA149 and the start of Phase III trials with NVA237.  In addition the Company received milestone payments for the development of VR315 in both Europe and the US.

Vectura and Sandoz announced the revision of the VR315 development programme with the US rights returning to Vectura.  Good clinical progress was made across the portfolio with positive Phase II data for both NVA237 and VR040 and QVA149 commenced Phase III studies.  In August 2010 GlaxoSmithKline signed a worldwide non-exclusive agreement to license some of Vectura’s dry powder drug formulation patents in relation to two late stage development compounds in GSK’s respiratory product pipeline.   Vectura closed its laboratory facilities in Nottingham at the end of 2010 and consolidated its formulation activities on the Chippenham site with the Cambridge site continuing to specialise in inhaler device development.